Drug intelligence / Profile preview

raxtozinameran

Development stage: Approved
Lead developer: Pfizer
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Raxtozinameran is a monovalent, nucleoside-modified messenger RNA (mRNA) vaccine developed by Pfizer and BioNTech for the prevention of COVID-19. It is specifically adapted to target the spike protein of the SARS-CoV-2 Omicron XBB.1.5 subvariant. As part of the Comirnaty family of vaccines, raxtozinameran functions by delivering mRNA encapsulated in lipid nanoparticles into host cells, which then translate the genetic sequence into the viral spike protein to elicit an immune response, including the production of neutralizing antibodies and T-cell activation. It was authorized and recommended for use during the 2023-2024 vaccination season to address the evolving landscape of SARS-CoV-2 variants.

Brand names: Comirnaty Omicron XBB.1.5
Other names: BNT162b2 (XBB.1.5)Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula)monovalent Omicron XBB.1.5 vaccine

Targets

ACE2 (Angiotensin-converting enzyme 2)SARS-CoV-2 spike

Beyond the preview

Go deeper on raxtozinameran.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on raxtozinameran.

Explore the full profile